Sewanti Limaye

Sewanti Limaye

Auto-generated profile, based on publicly available information

Sewanti Limaye

Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
PBPhilippe L. Bedard
Philippe L. Bedard
SLShuli Li
Shuli Li
KWKari B Wisinski
Kari B Wisinski
EYEddy Yang
Eddy Yang
SLSewanti A. Limaye
Sewanti A. Limaye
KFKeith T. Flaherty
Keith T. Flaherty
PURPOSE: National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family tyrosine kinase inhibitor, in patients with ERBB2-activating mutations. METHODS: Eligible patients had selected ERBB2 single-nucleotide variants or insertions/deletions detected by the National Cancer Institute–Molecular Analysis for Therapy Choice next-generation sequencing assay. Patients had performance status ≤ 1, left ventricular ejection fraction > 50%, grade ≤ 1 diarrhea, and no prior human epidermal growth factor receptor 2 (HER2) therapy. Patients received afatinib 40 mg once daily in 28-day cycles. The primary end point was objective response rate (ORR). Secondary end points were 6-month progression-free survival, overall survival, toxicity, and molecular correlates. RESULTS: A total of 59 patients were assigned and 40 were enrolled. The median age was 62 years, 78% were female, 68% had performance status = 1, and 58% had received > 3 prior therapies. The confirmed ORR was 2.7% (n = 1 of 37; 90% CI, 0.14 to 12.2), and 6-month progression-free survival was 12.0% (90% CI, 5.6 to 25.8). A confirmed partial response occurred in a patient with adenocarcinoma of extra-mammary Paget disease of skin who progressed after cycle 6. Two unconfirmed partial responses were observed (low-grade serous gynecological tract and estrogen receptor–positive/HER2-negative immunohistochemistry breast ductal carcinoma). Of 12 patients with breast cancer, 1 additional patient with lobular carcinoma (estrogen receptor–positive/HER2 fluorescent in situ hybridization) had a 51% reduction in target lesions but progressed because of a new lesion at cycle 6. The most common (> 20%) treatment-related adverse events were diarrhea (68%), mucositis (43%), fatigue (40%), acneiform rash (30%), dehydration (27%), vomiting (27%), nausea (27%), anemia (27%), and anorexia (22%). Four patients (11%) discontinued because of adverse events. CONCLUSION: Although afatinib did not meet the prespecified threshold for antitumor activity in this heavily pretreated cohort, the response in a rare tumor type is notable. The safety profile of afatinib was consistent with prior studies.

29 January 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
HSHardik Sheth
Hardik Sheth
RPRamya Pragya
Ramya Pragya
SKShama Kovale
Shama Kovale
MDMandar Deshpande
Mandar Deshpande
RMRajesh Mistry
Rajesh Mistry
SLSewanti Limaye
Sewanti Limaye

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
HSHardik Sheth
Hardik Sheth
PKPrashant Kumar
Prashant Kumar
ASAditya Shreenivas
Aditya Shreenivas
JSJanani Sambath
Janani Sambath
RPRamya Pragya
Ramya Pragya
SLSewanti Limaye
Sewanti Limaye

1 June 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
AMArun K. Mankan
Arun K. Mankan
ASAbhishek Shankar
Abhishek Shankar
SLSewanti Limaye
Sewanti Limaye
BAB.S. Ajaikumar
B.S. Ajaikumar
PNPrajakta Nachane
Prajakta Nachane
KSKamal S. Saini
Kamal S. Saini
Executing global clinical trials for cancer is a long, expensive, and complex undertaking. While selecting countries global studies, sponsors must consider several aspects including patient pool, quality of trained investigators, competing trials, availability of infrastructure, and financial investment versus returns. With a large, often treatment-naïve, and diverse patient pool, relatively low cost, good quality health care facilities in urban areas, and a robust and well-trained workforce, India offers several advantages for conducting oncology clinical trials. However, there remains challenges, including a shifting regulatory environment in recent decades. With the implementation of the New Drugs and Clinical Trial Rules in 2019, India's regulatory atmosphere seems to have stabilized. In this article, we present a review of the evolving clinical trial landscape in India, highlight the current regulatory scenario, and discuss the advantages and challenges of selecting India as a potential location for conducting global oncology clinical trials.

1 May 2021 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
HSHardik Sheth
Hardik Sheth
PKPrashant Kumar
Prashant Kumar
SLSewanti Limaye
Sewanti Limaye
There is limited data on management of metastatic nonsmall cell lung cancer (NSCLC) in the elderly population due to lack of representation of this subset in clinical trials. The projected representation of elderly population of patients globally is expected to rise significantly in the years to come. It is imperative to understand the specific challenges and opportunities in management of elderly with NSCLC. Even in the elderly, the medical management of advanced NSCLC begins with driver mutation testing on lung biopsy. Once the patient is classified as driver mutation positive or negative, they can either be treated with a single-agent-targeted therapy or with immunotherapy and chemotherapy or after programmed death ligand 1 (PDL-1) assessment, with immunotherapy alone. After starting the appropriate therapy, the disease needs to be monitored at every 3 months with reassessment scans. Treatment in elderly should be designed as per their functional and not chronological age, and geriatric assessment scales should be utilized wherever possible to understand the functional age of the patient.

17 November 2020 in Oncotarget
Verified
Journal Article
Open access
SLSewanti Limaye
Sewanti Limaye
PKPrashant Kumar
Prashant Kumar
RPRamya Pragya
Ramya Pragya
JSJanani Sambath
Janani Sambath
DPDarshana Patil
Darshana Patil
RDRajan Datar
Rajan Datar
// Sewanti Limaye1, Prashant Kumar2,3,4, Ramya Pragya1, Janani Sambath3,4, Darshana Patil2, Ajay Srinivasan2, Sachin Apurva2, Navin Srivastava2, Sanket Patil2, Revati Patil2, Vineet Datta2, Dadasaheb Akolkar2 and Rajan Datar2 1 Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India 2 Datar Cancer Genetics Limited, Nasik, Maharashtra, India 3 Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India 4 Manipal Academy of Higher Education, Manipal, Karnataka, India Correspondence to: Sewanti Limaye, email: sewanti.limaye@gmail.com Prashant Kumar, email: prashant.kumar@datarpgx.org Keywords: high grade serous ovarian cancer; androgen receptors; bicalutamide Received: July 16, 2020 Accepted: October 27, 2020 Published: November 17, 2020 Copyright: © 2020 Limaye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Ovarian cancer is common gynaecological malignancy and a leading cause of death among women. Despite the advances in treatment strategies, majority of patients present with recurrence after first- or second-line treatment. Targeted therapy that has proven to be effective in other advanced or metastatic solid tumors have also demonstrated its efficacy in ovarian cancer. Recent studies have shown that the androgen receptor (AR) signalling is involved in pathogenicity and progression of cancer. Current observations suggest AR could be a potential target in managing the disease. In this case report we present a patient with high grade serous ovarian cancer (HGSOC) with multiple relapses with excellent disease control on AR inhibition with bicalutamide.